University College London
Institute of Cardiovascular Sciences, The Hatter Cardiovascular Institute
Derek J Hausenloy
Cardioprotection: Bench to Bedside
Ischaemic heart disease (IHD) is the leading cause of death and disability in Singapore and worldwide. As such novel treatment strategies are required to protect the heart against the detrimental effects of acute ischaemia/reperfusion injury (IRI) - this is essential and is required to preserve cardiac function and prevent the onset of heart failure in patients with IHD. This is particularly important in IHD patients undergoing coronary artery bypass graft (CABG) surgery and in IHD patients presenting with an acute myocardial infarction (AMI) in which mortality and morbidity remain significant. Therefore, our main research objective is to discover novel therapeutic strategies for protecting the myocardium from acute IRI (a strategy termed ‘cardioprotection’).
We use a translational approach to cardioprotection with the identification of novel therapeutic targets at the laboratory ‘bench’ using pre-clinical models of acute IRI, and investigate their therapeutic potential in proof-of-concept clinical studies and multi-centre clinical outcome randomized controlled trials in IHD patients undergoing CABG surgery and in IHD patients presenting with an AMI.
- Mitochondrial function/cell signaling
- Small animal acute IRI models (ex vivo and in vivo)
- STEMI/CABG cardioprotection clinical studies
- Cardiac MRI
Interested in collaborating on
Cardioprotection collaboration in experimetnal and clinical settings.